scispace - formally typeset
G

Guido Kroemer

Researcher at Institut Gustave Roussy

Publications -  1546
Citations -  294816

Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.

Papers
More filters
Journal ArticleDOI

Non‐apoptotic functions of apoptosis‐regulatory proteins

TL;DR: The unconventional roles of the apoptotic core machinery from a functional perspective are summarized and their pathophysiological implications are discussed.
Journal ArticleDOI

Methionine Restriction Extends Lifespan in Progeroid Mice and Alters Lipid and Bile Acid Metabolism.

TL;DR: Dietary intervention constitutes a feasible approach for modulating metabolism and improving the health span and lifespan in normal mice and suggests the existence of a metabolic pathway involved in the longevity extension achieved by MR and support the possibility of dietary interventions for treating progeria.
Journal ArticleDOI

Trial Watch: DNA vaccines for cancer therapy

TL;DR: The latest advances on the use of DNA-based vaccines in cancer therapy are discussed, discussing the literature that has been produced around this topic during the last 13 months as well as clinical studies that have been launched in the same time frame to assess the actual therapeutic potential of this intervention.
Journal ArticleDOI

Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas.

TL;DR: Results indicate that activation of caspases is not sufficient to kill U1810 cells and rather suggests an important role for the AIF-mediated mitochondrial-mediated death pathway, and a transfection-enforced overexpression of AIF did enhance STS-mediated cell killing.
Journal ArticleDOI

Targeting p53 to mitochondria for cancer therapy.

TL;DR: Novel approaches of gene therapy have been designed in which p53 is specifically targeted to mitochondria and have been demonstrated to inhibit the growth of human cancer xenografts in immunodeficient mice, suggesting a number of distinct strategies can be employed to achieve the therapeutic induction of MOMP in cancer cells.